BAVA.CO - Bavarian Nordic A/S
| Previous Close | 188.30 |
| Open | 189.00 |
| Bid | 192.90 x 0 |
| Ask | 193.85 x 0 |
| Day's Range | 189.00 - 194.75 |
| 52 Week Range | 171.00 - 411.00 |
| Volume | |
| Avg. Volume | 428,682 |
| Market Cap | 15.065B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | 45.50 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Those at high risk of mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that the regimen is more effective at preventing infection than one shot. The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States. The study of the vaccine's real-world use, conducted between Aug. 19, 2022 and March 31, 2023 among 917 people, showed it was 85.9% effective overall in preventing disease after two doses, compared with 75.2% after one dose.
- Reuters
People at high risk to mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that two doses were more effective at preventing infection than one, officials said on Thursday. The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States.
- Motley Fool
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Emergent BioSolutions (NYSE: EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500's gain of 0.3%. The buyer is Denmark-headquartered peer Bavarian Nordic, which has handed over $270 million for the set of assets.
- Thomson Reuters StreetEvents
Q1 2023 Emergent BioSolutions Inc Earnings Call
Q1 2023 Emergent BioSolutions Inc Earnings Call
- Reuters
UPDATE 1-CDC panel recommends Bavarian Nordic's mpox vaccine for all adults at risk
The panel of outside experts voted unanimously in favor of use of two doses of the vaccine, and finalizing the interim guidelines provided by CDC during the mpox outbreak in the United States. The recommendation of the committee is based on studies that showed vaccine effectiveness of 66%-83% for patients with full vaccination and 36%-86% for partial vaccination with no severe adverse affect. The intradermal injection of Jynneos – that is between the layers of skin – is the preferred form of administration for adults during the outbreak, but is also approved as a subcutaneous injection, or below the skin.
- Reuters
UPDATE 1-Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln
Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023. The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. "Travel vaccines are seeing a rebound after the COVID-19 pandemic," the company said.
- Reuters
Bavarian Nordic to buy travel vaccine portfolio for up to $380 million
Bavarian Nordics makes the only approved mpox vaccine and started receiving massive orders last year as the virus became a global issue. The company expects 2023 revenue of about 6 billion Danish crowns ($863 million) against the 3.15 billion crowns in preliminary 2022 results, with 4.4 billion crowns coming from mpox and smallpox vaccined contracts alone. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to reach 2.2 billion crowns this year, up from 329 million crowns in the preliminary results for 2022.
- Reuters
J&J and Merck Ebola vaccines produce lasting antibodies in children and adults -studies
Ebola vaccines developed by Johnson & Johnson and Merck & Co produced virus-fighting antibodies and appear to be safe in children and adults, according to data from two studies published on Wednesday. Both companies' vaccines produced antibodies 14 days after the first of two shots and were detectable at varying levels in both children and adults for one year, data from the studies conducted in Western Africa showed. The vaccines are designed to target the Zaire strain of the virus, not the Sudan strain of Ebola that recently caused an outbreak and at least 56 deaths in Uganda.
- Motley Fool
Bavarian Nordic's Quarterly Earnings Pop on Monkeypox Vaccine
Denmark, which ranks among the world's happiest countries year in and year out, has another reason to smile. On Wednesday, Danish drugmaker...
- Reuters
PAHO secures 100,000 monkeypox vaccine doses for Latin America and Caribbean
The Pan American Health Organization (PAHO) has lined up a supply of monkeypox vaccine for Latin America and the Caribbean, as the Americas becomes a new epicenter for the rapidly spreading disease. "PAHO has secured an agreement with Bavarian Nordic to provide 100,000 doses of monkeypox vaccines to Latin America and the Caribbean through the revolving fund," PAHO Director Dr. Carissa Etienne told a press briefing on Wednesday.
- Reuters
UPDATE 1-EU secures more doses of Bavarian monkeypox vaccine
The European Union said on Wednesday it had secured an additional 170,920 doses of the monkeypox vaccine developed by biotech firm Bavarian Nordic amid concerns about the outbreak of the disease. The new order more than doubles the EU's supply of the vaccine, bringing the total number of doses directly purchased by the EU to nearly 335,000. The additional doses will be available for delivery before the end of the year, while shots that were purchased earlier are currently being distributed, the EU Commission said.
ReutersUPDATE 2-Monkeypox outbreak can be eliminated in Europe, WHO says
It is possible to eliminate the monkeypox outbreak in Europe, World Health Organization officials said on Tuesday, highlighting evidence that case counts are slowing in a handful of countries. There are encouraging signs of a sustained week-on-week decline in the onset of cases in many European countries, including France, Germany, Portugal, Spain and Britain, as well as a slowdown in some parts of the United States, despite scarce vaccine supplies. "We believe we can eliminate sustained human-to-human transmission of monkeypox in the (European) region," said WHO Regional Director for Europe Hans Kluge.
- Yahoo Finance
More monkeypox vaccine doses expected by late September: U.S. officials
Monkeypox cases could be coming down, but the CDC is still seeing a concerning rise in much of the U.S.
- Reuters
UPDATE 1-Very few in the U.S. getting full monkeypox vaccine series - CDC chief
Very few people who have gotten monkeypox shots in the United States have received the second dose needed for full protection, U.S. Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky said on Friday. Walensky said the CDC expected to gain more insight into the trend. More than 207,000 doses of Bavarian Nordic's Jynneos vaccine were given as of Aug. 23 in the 19 jurisdictions reporting data to the CDC, Walensky said.
- Bloomberg
Senate Committee Plans Hearings on Response to Monkeypox Outbreak
(Bloomberg) -- US lawmakers will look to press Biden administration health officials on their response to the growing monkeypox outbreak in a Senate hearing planned for next month, according to people familiar with the matter.The Health, Education, Labor and Pensions Committee is planning the hearing on monkeypox for mid-September, according to the people, who asked not to be identified because the information isn’t public. Concerns about monkeypox are rising, with both Republican and Democratic
- Yahoo Finance
Bavarian Nordic sees boost from monkeypox vaccine in Q2
Monkeypox vaccine maker Bavarian Nordic sees strong sales in Q2 on growing global demand.
- Thomson Reuters StreetEvents
Edited Transcript of BAVA.CO earnings conference call or presentation 24-Aug-22 12:00pm GMT
Q2 2022 Bavarian Nordic A/S Earnings Call
- Reuters
UPDATE 2-European shares end 3-day losing streak as defensives pull higher
European shares eked out gains by the close on Wednesday, buoyed by a rise in defensive stocks, though worries over a looming energy crisis and gloomy growth outlook kept gains in check. Defensive sectors including healthcare led gains, while miners fell 1.8%, the most across European sectors. "The continued surge in European gas prices, and likelihood that they will remain extremely high, means that the euro zone will probably suffer a deeper recession than we had previously anticipated," said Jack Allen-Reynolds, senior Europe economist at Capital Economics.
- Reuters
Miners drag European bourses lower as energy crisis looms
European shares extended a selloff on Wednesday, as investors fretted over an energy crisis and gloomy growth outlook, while hawkish comments on U.S. Federal Reserve monetary policy further dented sentiment. The pan-European STOXX 600 was down 0.2%, as of 0716 GMT, to hover near one-month lows on downbeat performances by miners. Investors were cautious ahead of the Jackson Hole symposium after Minneapolis Federal Reserve Bank President Neel Kashkari on Tuesday reiterated the Fed's focus on controlling inflation ahead of all else.
- Reuters
UPDATE 2-Britain to pilot using smaller doses of monkeypox vaccine to boost supply
Britain is following the United States and Europe in making the most of limited supply of the monkeypox vaccine by administering smaller doses of the shot, health officials said on Monday. Three National Health Service sites are set to begin a pilot testing of the so-called fractional dosing approach, which involves using one vial of the vaccine to administer up to five separate doses - instead of a single dose - by injecting a smaller amount in between layers of the skin (intradermal injection). The Bavarian Nordic vaccine - called Jynneos, Imvanex and Imvamune, depending on geography - was designed to be injected into a layer of fat beneath the skin, known as a subcutaneous injection.
- Yahoo Finance
Monkeypox doses ready by December: Michigan manufacturer
U.S. based monkeypox vaccine manufacturer targets December for first batch of doses for delivery.
- Zacks
Bavarian Nordic (BVNRY) Surges 8.1%: Is This an Indication of Further Gains?
Bavarian Nordic (BVNRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks
Here's Why Momentum in Bavarian Nordic (BVNRY) Should Keep going
Bavarian Nordic (BVNRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- Yahoo Finance Video
U.S. negotiates terms with Bavarian Nordic on monkeypox vaccine production
Yahoo Finance's Anjalee Khemlani breaks down the new deal the U.S. and sole monkeypox vaccine maker have reached to speed up vaccine distribution.
